HGF (Hepatocyte Growth Factor): Complete Research Profile — c-Met Receptor Signaling, Liver Regeneration, Angiogenesis, and Multi-Domain Research Applications (2026)

# HGF (Hepatocyte Growth Factor): Complete Research Profile — c-Met Receptor Signaling, Liver Regeneration, Angiogenesis, and Multi-Domain Research Applications (2026)

Hepatocyte Growth Factor (HGF) — also historically termed Scatter Factor (SF) — is a pleiotropic paracrine cytokine that operates through the receptor tyrosine kinase c-Met to coordinate an extraordinarily broad range of cellular programs: mitogenesis, motogenesis, morphogenesis, anti-apoptosis, and angiogenesis. Originally isolated from the serum of partially hepatectomized rats as a potent hepatocyte mitogen in the late 1980s, HGF has since emerged as one of the most widely studied growth factors in modern biology. Its regulatory scope spans embryonic organogenesis, postnatal tissue homeostasis, wound repair, neuroprotection, and oncogenic transformation. For researchers in cellular biology, cancer pharmacology, regenerative medicine, and tissue engineering, recombinant HGF protein and c-Met pathway tools constitute essential reagents for dissecting these complex biological programs. All HGF research applications described here are strictly for laboratory use only (Research Use Only / RUO) and do not constitute clinical advice or protocols for human or animal use.

Molecular Structure of HGF

HGF is synthesized as a single-chain inactive precursor (pro-HGF) of approximately 728 amino acids (~90 kDa). Proteolytic cleavage between Arg494 and Val495 by serine proteases — including hepatocyte growth factor activator (HGFA), matriptase, and hepsin — generates the biologically active heterodimer. The mature active form consists of an α-chain (~69 kDa) and a β-chain (~34 kDa) linked by a single disulfide bond.

Domain Architecture

The α-chain carries all high-affinity receptor-binding determinants and comprises:

• •N-terminal (N) domain (residues 28–96): Contains a hairpin loop involved in heparan sulfate proteoglycan (HSPG) binding and receptor activation
• •Kringle 1 (K1) (residues 97–207): Primary c-Met-binding kringle; essential for receptor activation
• •Kringle 2 (K2) (residues 208–288): Contributes to heparin binding
• •Kringle 3 (K3) (residues 289–368): Structural role
• •Kringle 4 (K4) (residues 369–449): Structural scaffolding

The β-chain adopts an inactive serine protease-like fold (residues 495–728). Unlike typical serine proteases, the catalytic triad residues are replaced such that no enzymatic activity exists — the domain is catalytically dead yet structurally intact. This pseudo-protease domain mediates the low-affinity c-Met interaction and positions the α-chain for high-affinity engagement.

Natural Splice Isoforms

Two naturally occurring truncated isoforms have been extensively characterized:

• •NK1 (residues 28–210; N-domain + K1): Acts as a partial agonist in the presence of heparan sulfate but as an antagonist in the absence of HSPGs. The crystal structure of NK1 was solved at 2.0 Å resolution, revealing a dimerization interface critical for c-Met activation (PMID 9817840).
• •NK2 (residues 28–289; N-domain + K1 + K2): Selectively activates motogenesis and cell survival via ERK signaling but not proliferation, due to impaired Akt activation — an important tool for dissecting pathway-selective c-Met outputs (PMC7751956).
• •NK4 (all four kringles without β-chain): Functions as a competitive c-Met antagonist and anti-angiogenic agent in research models.

Domain organization and the functional implications of each structural element are reviewed comprehensively in (PMID 9524765) and (PMID 9678607).

The c-Met Receptor: Structure and Activation Mechanism

The c-Met receptor tyrosine kinase (encoded by the MET proto-oncogene; also designated CD120 or HGFR) is a single-pass transmembrane glycoprotein processed into a disulfide-linked heterodimer of a short extracellular α-chain and a larger β-chain spanning the membrane. The extracellular portion comprises a SEMA domain (the primary HGF-binding interface), a PSI (plexin-semaphorin-integrin) domain, and four IPT (immunoglobulin-plexin-transcription factor) repeats. The intracellular region harbors the juxtamembrane regulatory segment, the bilobal kinase domain, and the C-terminal multifunctional docking site.

Activation Sequence

1. Ligand binding: HGF engages c-Met via a two-step mechanism — the β-chain makes initial low-affinity contact with the SEMA domain; the K1 kringle of the α-chain then inserts into a high-affinity binding pocket.

2. Receptor dimerization: HGF-induced c-Met homodimerization positions the two kinase domains for trans-phosphorylation.

3. Activation loop phosphorylation: Phosphorylation of Y1234 and Y1235 within the kinase activation loop stabilizes the active conformation.

4. Docking site recruitment: Phosphorylation of Y1349 and Y1356 in the multifunctional docking tail creates binding sites for SH2-domain-containing adaptors, initiating downstream cascades.

HGF/c-Met Downstream Signaling Networks

The phosphorylated c-Met docking site functions as a scaffold for a remarkably promiscuous set of signaling adaptors. Unlike many receptor tyrosine kinases that activate one or two primary pathways, c-Met simultaneously engages multiple downstream networks, which accounts for the multi-program biological output of HGF:

RAS/MAPK Cascade

Grb2 recruits SOS to activate RAS, which drives the RAF→MEK→ERK cascade. Sustained ERK activation is required for HGF-induced branching tubulogenesis in glandular epithelial models. ERK substrates include transcription factors ELK1, ETS1, and c-Myc, linking HGF signaling to gene expression programs controlling proliferation and differentiation.

PI3K/AKT/mTOR Axis

GAB1 (GRB2-associated binder 1) serves as a key amplifying scaffold that recruits PI3K to the activated c-Met complex. PI3K converts PIP2 to PIP3, enabling PDK1-mediated phosphorylation and activation of AKT. AKT subsequently activates mTORC1 and suppresses pro-apoptotic proteins (BAD, caspase-9), generating potent survival and protein synthesis signals.

JAK/STAT3 Pathway

c-Met directly phosphorylates and activates STAT3, which dimerizes and translocates to the nucleus to regulate genes encoding survivin, Bcl-xL, cyclin D1, and VEGF. STAT3 activation is particularly important in oncogenic c-Met contexts and contributes to immune evasion in the tumor microenvironment (PMC11354629).

SRC Kinase Integration

Src is activated downstream of c-Met and phosphorylates focal adhesion kinase (FAK), promoting cytoskeletal reorganization, lamellipodia formation, and the epithelial-to-mesenchymal transition (EMT).

Wnt/β-Catenin Crosstalk

In hepatocytes, HGF/c-Met signaling stabilizes β-catenin through AKT-mediated GSK-3β inhibition, augmenting Wnt-responsive transcriptional programs that govern hepatocyte proliferation and zonation.

NF-κB Pathway

In inflammatory contexts, HGF/c-Met activates NF-κB via IKK, contributing to anti-apoptotic gene expression and modulating innate immune responses.

An integrative review of these convergent pathways in the cancer context is provided in (Molecular Cancer, 2018).

HGF in Liver Regeneration Research

The hepatic regeneration axis is perhaps the most historically significant biological role of HGF. Following 70% partial hepatectomy in rodents, circulating HGF levels increase 10- to 20-fold within hours, serving as the primary mitogenic trigger for the regenerative response. Both endocrine (liver-derived circulating pro-HGF) and paracrine (stellate cell-derived HGF within the liver) pools contribute to this response.

Key mechanistic insights from research models:

• •Conditional knockout of c-Met in hepatocytes severely impairs liver regeneration, confirming obligate receptor requirement (PMC3299882).
• •HGF drives G1→S phase entry in hepatocytes via ERK-dependent cyclin D1 induction.
• •HGF simultaneously suppresses TGF-β1-mediated hepatocyte growth arrest, providing a "pro-regenerative override" signal.
• •HGF/c-Met promotes hepatic progenitor (oval) cell expansion during chronic liver injury when mature hepatocyte proliferation is impaired.

The HGF/c-Met axis in liver regeneration is reviewed in detail in (PMC8968572).

HGF in Embryonic Organogenesis

Genetic studies have established HGF/c-Met as essential for the development of multiple organ systems. Gene knockout of either Hgf or Met in mice results in embryonic lethality by E13-E16, with defects including:

• •Liver: Severely reduced hepatocyte number; failure of hepatic cord formation
• •Placenta: Reduced labyrinthine trophoblast invasion leading to placental insufficiency
• •Skeletal muscle: Failure of long-range migration of muscle progenitor cells from the hypaxial dermomyotome to the limb buds — the most dramatic organogenetic phenotype, establishing HGF/c-Met as the "scatter" signal enabling muscle cell colonization of the developing limb
• •Kidney: Defects in ureteric bud branching morphogenesis leading to reduced nephron endowment

The tissue-specific roles of HGF isoforms including NK1, NK2, and full-length HGF in organogenesis versus fibrotic remodeling are reviewed in (PMID 28548073).

Angiogenesis and Vascular Research

HGF is a direct and potent angiogenic factor that acts independently of VEGF pathways:

• •Endothelial proliferation: HGF promotes S-phase entry in human umbilical vein endothelial cells (HUVECs) via PI3K/AKT and ERK cascades.
• •Endothelial migration: HGF activates RAC1 and CDC42, driving lamellipodia extension and directional cell migration; this motogenic activity originally named HGF as "Scatter Factor" in its independent discovery stream.
• •Tube formation: HGF stimulates three-dimensional lumen formation in Matrigel assays, a widely used in vitro angiogenesis model.
• •Lymphangiogenesis: c-Met is expressed on lymphatic endothelial cells, and HGF promotes lymphatic vessel sprouting in research models.

In the tumor vasculature context, cancer-associated fibroblasts (CAFs) constitutively secrete HGF, creating a paracrine loop that sustains pathological angiogenesis and drives resistance to anti-VEGF biologics. This CAF-HGF-c-Met axis represents an active area of translational cancer research.

Wound Healing and Tissue Repair

HGF exerts multi-compartment effects in wound healing research models:

• •Re-epithelialization: HGF stimulates keratinocyte migration and proliferation via c-Met activation; keratinocytes express high levels of c-Met, and HGF is released from dermal fibroblasts and platelets at wound sites.
• •Dermal fibroblast modulation: HGF attenuates TGF-β1-mediated myofibroblast differentiation, reducing fibrosis in healing wounds — a mechanism with relevance to hypertrophic scar and keloid research.
• •Anti-fibrotic signaling: HGF suppresses hepatic stellate cell activation, reducing collagen synthesis; similar anti-fibrotic effects have been demonstrated in pulmonary, renal, and cardiac fibrosis research models.
• •Mast cell chemoattraction: HGF recruits mast cells to wounds, contributing to the early inflammatory phase.

Neuroprotection and Neurological Research

HGF/c-Met signaling in the central and peripheral nervous systems has attracted significant research attention:

• •Motor neuron survival: c-Met is expressed on spinal motor neurons; HGF supports survival in ALS and spinal muscular atrophy (SMA) research models.
• •Cerebral ischemia: Intrathecal or intraventricular HGF administration reduces infarct volume and promotes neurovascular repair in rodent stroke models, partly through STAT3-mediated anti-apoptotic gene expression (PMC4280917).
• •Parkinson's disease: HGF protects dopaminergic neurons in MPTP and 6-OHDA toxin models; the HGF receptor agonist Dihexa (see Dihexa Research Profile) exploits c-Met to enhance synaptic connectivity in cognitive research contexts.
• •Peripheral nerve regeneration: Schwann cells upregulate HGF after nerve injury; HGF promotes axonal elongation and Schwann cell migration in sciatic nerve crush models.
• •Blood-Brain Barrier (BBB): HGF strengthens tight junction protein expression (ZO-1, occludin, claudin-5) in brain endothelial cells, providing a potential mechanism for BBB restoration research.

HGF/c-Met in Cancer Biology Research

The HGF/c-Met axis represents one of the most intensively investigated oncogenic signaling systems. Dysregulation occurs through multiple mechanisms:

c-Met Alterations in Cancer

• •MET amplification: Copy number gain drives constitutive c-Met kinase activity; common in gastric cancer, NSCLC, and glioblastoma.
• •MET exon 14 skipping mutation (METex14): A juxtamembrane domain mutation that impairs ubiquitin-mediated receptor degradation, leading to prolonged c-Met signaling. This alteration is the driver mutation for capmatinib and tepotinib approval in NSCLC research.
• •MET overexpression: Elevated c-Met protein without gene amplification; observed in colorectal, breast, pancreatic, thyroid, and head & neck cancers.
• •Activating point mutations: Y1248H, M1268T, and D1246N in the kinase domain cause constitutive activation; enriched in hereditary papillary renal cell carcinoma.

HGF Paracrine Loops

In many solid tumors, HGF secreted by cancer-associated fibroblasts (CAFs) drives c-Met signaling in cancer cells in an autocrine/paracrine fashion, contributing to:

• •Invasion and metastasis via EMT induction
• •Resistance to EGFR inhibitors (e.g., gefitinib, erlotinib) through compensatory RAS/MAPK activation
• •Immune exclusion via STAT3-mediated PD-L1 upregulation
• •Cancer stem cell self-renewal

Comprehensive reviews of HGF/c-Met in gastric (PMC11334049) and NSCLC (PMC11354629) cancers were published in 2024.

Research Tools and Reagents

Recombinant HGF Proteins

• •Full-length HGF heterodimer (cleaved two-chain form): Used in cell biology, angiogenesis, scatter assays, and organoid culture. Standard concentration range in culture media: 10–100 ng/mL.
• •Pro-HGF (single-chain): Useful for studying HGFA-dependent activation in extracellular matrix-mimicking systems.
• •NK1 and NK2 fragments: Used for pathway-selective studies (motogenesis vs. mitogenesis dissection) and competitive receptor occupancy experiments.

c-Met Kinase Inhibitors (Small Molecule)

Anti-HGF Biologics (Research Antibodies)

• •Rilotumumab (AMG102): Anti-HGF neutralizing monoclonal antibody; blocks HGF binding to c-Met without affecting c-Met itself — useful for isolating ligand-dependent vs. ligand-independent c-Met activity in experimental designs.
• •Ficlatuzumab (AV-299): Anti-HGF antibody used in gastric and lung cancer research models.

Readout Assays for HGF/c-Met Research

• •Scatter assay (MDCK cells): The classic functional assay for HGF; MDCK epithelial colonies dissociate ("scatter") upon HGF treatment via c-Met-mediated ERK/RAC1 activation.
• •Branching tubulogenesis (MDCK in Matrigel): 3D assay producing branching tubules; requires sustained MAPK and STAT3 activation — tests full "morphogenetic" program.
• •Wound scratch migration: Quantifies HGF-stimulated cell motility in 2D monolayers.
• •Boyden chamber invasion: Tests invasion through Matrigel-coated inserts.
• •c-Met phosphorylation (pY1234/Y1235): ELISA or proximity ligation assay for receptor activation status.
• •GAB1 phosphorylation (pY627): Downstream readout indicating PI3K recruitment.

HGF Isoforms in Fibrosis Research

The relationship between HGF and fibrosis is context-dependent and requires careful experimental interpretation:

• •Acute/moderate injury: HGF is anti-fibrotic — it suppresses hepatic stellate cell (HSC) activation, reduces collagen deposition, and promotes resolution via MMP upregulation.
• •Chronic high-level HGF: Paradoxically, constitutive HGF/c-Met signaling can sustain proliferative programs in activated HSCs under certain conditions.
• •NK1 isoform: In fibrotic lung research models, NK1 has demonstrated pro-fibrotic gene expression changes distinct from full-length HGF, illustrating that domain-specific signaling outputs matter (PMID 28548073).
• •Renal fibrosis: HGF attenuates TGF-β1-induced tubular EMT and interstitial fibroblast activation in cisplatin and unilateral ureteral obstruction (UUO) nephropathy research models.

Experimental Considerations for HGF Research

When designing HGF experiments in research settings, several technical factors merit attention:

• •Heparin/HSPG dependence: HGF binding to heparan sulfate proteoglycans on the cell surface and in the extracellular matrix is required for efficient c-Met activation in most cell types. Research media formulations with heparin supplement (typically 10–100 μg/mL) potentiate HGF activity and should be considered when establishing assay conditions.
• •Pro-HGF activation: Culture supernatants may contain pro-HGF that requires exogenous HGFA or matriptase to generate the active heterodimer. Cell-free systems should include activation enzyme when working with pro-HGF.
• •Receptor internalization/downregulation: c-Met undergoes rapid ubiquitin-mediated endocytosis after HGF stimulation (t½ ~30–60 min). Pulsed vs. continuous HGF treatment produces quantitatively different downstream outputs and should be specified in protocols.
• •Serum HGF contamination: Fetal bovine serum contains bioactive HGF and should be serum-starved before experiments requiring baseline c-Met activity measurements.
• •c-Met crosstalk with EGFR: In cancer cell models, EGFR and c-Met engage in bi-directional transactivation. Researchers targeting one receptor should control for the other.

HGF vs. Related Ligands in Multi-Growth Factor Research

HGF is often studied alongside other growth factors that share some biological outputs:

Summary: Research Utility Profile

HGF stands out among growth factors for the breadth and coherence of its biological program. From a research utility perspective:

• •Liver regeneration models: HGF/c-Met is the gold-standard paracrine driver system; genetic (cre-lox) and pharmacological (PHA-665752) tools allow precise dissection.
• •Organoid culture: Inclusion of HGF is routine in intestinal, hepatic, and pancreatic organoid protocols where it drives branching morphogenesis and epithelial expansion.
• •Cancer signaling research: METex14 models (NCI-H596, EBC-1) and c-Met-amplified lines (MKN45, GTL16) are well-validated in vitro platforms; capmatinib and tepotinib are the standard-of-care tool compounds.
• •Neuroprotection research: Dihexa (an HGF receptor agonist peptidomimetic) provides a BBB-permeable c-Met agonist alternative to recombinant HGF for CNS research — see related article: Dihexa: HGF Receptor Agonist for Cognitive and Synaptogenic Research.
• •Anti-fibrosis research: Full-length HGF and the NK2 isoform are used to interrogate TGF-β1 antagonism in stellate cell, tubular epithelial, and fibroblast systems.

Research Use Only Disclaimer

HGF, its isoforms (NK1, NK2, NK4), and all c-Met modulators described in this article are classified as research-use-only (RUO) laboratory reagents. They are intended exclusively for in vitro laboratory investigations and controlled in vivo research studies by qualified research professionals operating under appropriate institutional oversight. This content does not constitute medical advice, clinical guidance, or recommendation of any compound for use in humans or companion animals outside of authorized clinical trials.